Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name ROS1 mutant
Gene Variant Detail

ROS1 mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU 2
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Completed USA | AUS 0
NCT04609566 Phase II Brentuximab vedotin + Pembrolizumab Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors Recruiting USA | CAN 0
NCT03138889 Phase Ib/II NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors Terminated USA | FRA | ESP | DEU | AUS 0
NCT04524689 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05) Active, not recruiting USA | FRA | ESP 5
NCT05240131 Phase Ib/II Atezolizumab + GB1211 A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). Active, not recruiting FRA | ESP 1
NCT03475953 Phase Ib/II Avelumab + Regorafenib A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) Recruiting FRA 0
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT02314364 Phase II A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC Completed USA 0
NCT04094610 Phase Ib/II Repotrectinib A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 4
NCT05259319 Phase I Atezolizumab + Tiragolumab Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) Recruiting FRA 0
NCT03166631 Phase I BI 891065 + Ezabenlimab BI 891065 A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Terminated USA 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04925986 Phase II Pembrolizumab + Sitravatinib Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Terminated USA 0
NCT04903873 Phase Ib/II EU101 A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors Recruiting USA 1
NCT02097810 Phase I Entrectinib Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) Completed USA 1
NCT05502237 Phase III AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT02186821 Phase II Ceritinib Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Terminated USA 0
NCT03906071 Phase III Docetaxel Nivolumab + Sitravatinib Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL 3
NCT03696212 Phase Ib/II Grapiprant + Pembrolizumab Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma Terminated USA 0
NCT03175224 Phase Ib/II Vebreltinib APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 6
NCT03213652 Phase II Ensartinib Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Recruiting USA | AUS 1
NCT06003075 Phase II Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab Induction Chemo-Nivo in Unresectable Stage III NSCLC Recruiting USA 0
NCT04705818 Phase II Durvalumab + Tazemetostat Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) Recruiting FRA 0
NCT03391869 Phase III Ipilimumab + Nivolumab Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Recruiting USA 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05004116 Phase Ib/II Irinotecan + Repotrectinib + Temozolomide A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Recruiting USA 0
NCT04083976 Phase II Erdafitinib A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT04267237 Phase II Atezolizumab + Autogene cevumeran Atezolizumab A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer Withdrawn 0
NCT03708328 Phase I RO7121661 A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Active, not recruiting USA | NZL | FRA | ESP 2
NCT03396497 Phase I LYC-55716 + Pembrolizumab Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer Unknown status USA 0